Stealth BioTherapeutics Announces Promotion of Marty Redmon to Chief Research & Development Officer
Stealth BioTherapeutics Announces Promotion of Marty Redmon to Chief Research & Development Officer News provided by Share this article Share this article BOSTON, March 16, 2021 /PRNewswire/ -- Stealth BioTherapeutics (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced promotion of Marty Redmon, Ph.D., Executive Vice President, Discovery, Development, and Tech Ops, to the role of Chief Research & Development Officer, effective immediately. "Mart...
Source: prnewswire.com